Since its founding in 1806, Colgate-Palmolive has grown into a leading player in the household and personal care industry... Show more
Colgate-Palmolive occupies a defensive niche within consumer staples: its namesake oral care line accounts for more than 40% of total sales, complemented by personal care, home care, and the Hill's Pet Nutrition business, which contributes roughly a quarter of revenue. International markets generate about 70% of sales, with nearly half of the business tied to emerging regions — a structural advantage that exposes the company to faster-growing middle-class demand but also to currency volatility and geopolitical friction.
The medium-term positioning story is built around premiumization. Management is steering investment toward super-premium oral care innovation, price-tiered product architecture, and omnichannel demand generation, aiming to protect pricing power in a low-growth category environment. The Strategic Growth and Productivity Program (SGPP) targets $200–$300 million in annualized cost savings by 2028, with the majority of benefits flowing in 2027–2028 — capital that management intends to recycle into brand investment rather than flow entirely to the bottom line. Competitive threats persist from agile local players in emerging markets and from private-label pressure in the United States, where category volumes have been negative across several core categories.
Several forward-looking catalysts could reshape investor sentiment. First, earnings execution remains the primary swing factor: after raising its 2026 profit outlook to mid-single-digit Base Business earnings-per-share (EPS, or profit divided by shares outstanding) growth and improving its gross-margin view to roughly flat year over year, the company's ability to deliver on that upgrade through the second half of 2026 will be closely watched.
Second, the ramp-down of the private-label pet food exit — roughly a 260-basis-point drag that should abate in the back half of the year — could allow Hill's underlying momentum to become more visible. Third, the North America strategy reset, centered on accelerated innovation and refined promotional execution, represents a potential inflection point if volumes stabilize.
On the analyst front, sentiment has become more nuanced. Deutsche Bank upgraded the stock to Buy, while Morgan Stanley, Citi, Goldman Sachs, RBC Capital, and J.P. Morgan have maintained constructive ratings, with price targets ranging from about $87 to $110 and a consensus average near $98. Recent actions have moved in both directions — some firms trimming targets on cost concerns while others raised them on improved earnings visibility — underscoring a "Moderate Buy" posture rather than uniform conviction.
The trajectory of Colgate-Palmolive is tightly linked to a handful of macro variables. Global category growth has stabilized but remains subdued at roughly 1.5%–2.5%, well below historical norms, forcing the company to lean on pricing, mix, and innovation rather than broad volume expansion. Oil prices are a direct input risk: management has modeled oil near $110, with oil-byproduct spending such as resins, petrochemicals, fats, and oils expected up more than 20% year over year, and logistics costs up nearly 10%.
Inflation and consumer confidence shape demand elasticity across regions. In Latin America and parts of Asia, brand strength has allowed pricing to coexist with volume gains; in North America, tariff-driven margin pressure and cautious consumers have made the balance harder to maintain. Foreign exchange has been a tailwind recently but has been a negative for eight of the past ten years, making currency a recurring swing factor. Regulatory and trade-policy volatility, particularly in Latin America, adds a layer of uncertainty that management explicitly flags in its wider-than-usual guidance range.
For investors seeking a data-driven read on where Colgate-Palmolive and thousands of other assets may be headed, Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, ETF (exchange-traded fund), or other instrument may move bullish, bearish, or sideways over the next week or month. It is built to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad range of tradable instruments, with searchable prediction categories, historical context, and alert-oriented functionality. Whether you are monitoring a single ticker or scanning the wider market, the engine offers a neutral, systematic lens for trend analysis — a useful complement to the fundamental catalysts outlined above.
Looking toward 2026 and beyond, several structural themes will define Colgate-Palmolive's future outlook. Market expansion remains concentrated in emerging economies, where rising incomes and urbanization expand the addressable consumer base and support both premium and value-tier innovation. Margin sustainability hinges on whether productivity savings and revenue growth management can offset structurally higher input costs, making the SGPP program's 2027–2028 payout a pivotal element of the cost-structure evolution.
Technology transitions are also in motion: management is investing in data analytics, artificial intelligence, and supply-chain digitization, framing these as long-term competitive capabilities rather than near-term cost fixes. Capital allocation priorities — elevated advertising, selective pricing, and an established dividend — reflect a quality-compounder profile, though a premium forward price-to-earnings multiple relative to the household-products industry leaves less room for execution missteps. Consensus analyst expectations point to modest single-digit EPS growth in the coming years, implying that the stock forecast rests less on a macro rebound and more on disciplined execution of the 2030 strategy, emerging-market follow-through, and a credible North America reset.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CL has been closely correlated with PG. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if CL jumps, then PG could also see price increases.
a maker of oral, personal, and household products
Industry HouseholdPersonalCare
The 10-day moving average for CL crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 29 of 59 cases where CL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 49%.
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on CL as a result. In 31 of 68 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 46%.
The Moving Average Convergence Divergence (MACD) for CL just turned positive on October 06, 2026. Looking at past instances where CL's MACD turned positive, the stock continued to rise in 22 of 43 cases over the following month. The odds of a continued upward trend are 51%.
CL moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where CL advanced for three days, in 145 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
The Aroon Indicator entered an Uptrend today. In 118 of 277 cases where CL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 43%.
The 10-day RSI Indicator for CL moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 14 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 36%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
CL broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 8 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 29 (best 1 - 100 worst), indicating outstanding price growth. CL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 42 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock slightly better than average.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CL's P/B Ratio (329.104) is very high in comparison to the industry average of (20.672). P/E Ratio (38.358) is within average values for comparable stocks, (16.840). Projected Growth (PEG Ratio) (1.577) is also within normal values, averaging (1.518). Dividend Yield (0.022) settles around the average of (0.033) among similar stocks. P/S Ratio (3.331) is also within normal values, averaging (1.902).